top of page

All Posts


OmicXHealth Selected for TechCrunch Disrupt's Startup Battlefield 200
We're excited to share that OmicXHealth has been selected for the Startup Battlefield 200 at TechCrunch Disrupt 2026, in the Health & Wellness track. The Battlefield 200 is TechCrunch's flagship startup competition, drawing thousands of applicants down to 200 companies each year. Selection comes with a fully funded exhibitor booth at Disrupt, October 13–15 in San Francisco, along with access to pre-event programming with investors and founders, and a network of more than 1,70


Presenting at The Liver Meeting® (AASLD) 2026
Our abstract, "Early HCC Detection Using Multi-Expert Machine Learning on Cell-free Whole Genome Bisulfite Sequencing Data," has been accepted for poster presentation at The Liver Meeting® 2026 (AASLD), November 5–9 in Denver. The Liver Meeting® is the largest annual gathering of liver basic, translational, and clinical scientists and clinicians in the world — a must-attend event for anyone working in the field. The work reflects our core approach at OmicXHealth: combining mu


Non-Dilutive Funding: NIH/NCI Awards OmicXHealth an SBIR Grant
We're excited to share that OmicXHealth has received a Notice of Award for non-dilutive funding from the National Institutes of Health (NIH), through the National Cancer Institute (NCI), as part of the SBIR program. The award funds our blinded validation study of OmicXScreen for early hepatocellular carcinoma (liver cancer) detection at UT Southwestern alongside business and market assessment work to help de-risk our path to commercialization. We're deeply grateful for this s


Presenting at the CVC HCC Biomarker Symposium at UT Southwestern, Dallas
On May 16, I presented at the CVC HCC Biomarker Symposium at UT Southwestern's campus in Dallas, a day-long gathering that brought together industry and academia to share the latest research on hepatocellular carcinoma (HCC) screening and surveillance. I presented "Sequence Once, Detect Many: A Mixture-of-Experts Approach to Epigenomic HCC Surveillance" in the Industry and Biomarkers session, alongside teams from Fujifilm, Abbott, Exact Sciences, Universal Diagnostics, Curve


Peer-Reviewed: Our Early Cancer Detection Work Published in Military Medicine
Our manuscript on early cancer detection has been accepted and published in the peer-reviewed journal Military Medicine, a meaningful signal that this work holds up to scrutiny from the broader scientific community. This paper is based on our poster presentation at the DoD's Military Health System Research Symposium (MHSRS) in August 2025. You can read the paper here: https://academic.oup.com/milmed/article/191/Supplement_1/673/8751640
bottom of page
